Things To Expect From the Venetoclax?

In this population, the presence of ASXL1 mutation did not correlate with HCT level, total leukocyte count, platelet count, LDH level, spleen size, bleeding Enzalutamide complications, total thrombotic events, arterial thrombosis, and venous thrombosis (rcheck details patients. The prevalence of major thrombotic events, arterial thrombosis, and venous thrombosis did not significantly differ among ASXL1-mutated and wild-type PMF patients (P=1, P=0.437, and P=0.567, respectively). The prevalence of bleeding complications was significantly higher in ASXL1-mutant PMF patients than in those without ASXL1 mutation (42.1% and 12.1%, respectively; P=0.008). As regards the localization of bleeding events for PMF patients, 21.1% of ASXL1 mutant PMF patients experienced gastrointestinal bleeding and 10.5% intracranial hemorrhage; while gastrointestinal hemorrhage occurred in 1.7% of ASXL1 wild-type PMF patients. No intracranial hemorrhage developed in PMF patients without ASXL1 mutation (P=0.001). Consequently, the incidence of severe bleeding was significantly higher in ASXL1-mutated PMF patients compared with ASXL1 wild-type PMF patients (P=0.001). The frequency of JAK2V617F mutation did not differ between ASXL1-mutated and wild-type Histone demethylase PMF patients (73.7% and 75.9%, respectively; P=1). There was no significant difference in the quantitative JAK2V617F allele burdens between PMF patients with ASXL1 mutation and without the mutation (P=0.838). Moreover, the prevalence of JAK2V617F-positive patients with mutant allele burden in the upper quartile ranges did not differ between ASXL1 mutant and wild-type PMF patients (21.1% and 24.1%, respectively; P=0.957). Fourteen of 58 (24.1%) JAK2V617F-positive and 5 of 19 (26.3%) JAK2V617F-negative PMF patients displayed ASXL1 mutations (exon 12) (P=0.535).